Not finding it? Sign in to also search OpenAlex live.
-
Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance2020 British Journal of Urology article Medicine Prostate Cancer Diagnosis and Treatment Open access
Anirudh Tomer, Daan Nieboer, Monique J. Roobol, Anders S Bjartell, Ewout Willem Steyerberg, Dimitris Rizopoulos
29citations -
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial2026 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Désirée M F M van der Heijde, Philip J. Mease, Carle F. Paul, Frank Behrens, Laure Gossec, Yuko Kaneko, +16 more
2citations -
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
Philip J. Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Elke Boettcher, Sandra Navarra, +5 more
42citations -
Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy2020 European Journal of Nuclear Medicine and Molecular Imaging article Medicine Prostate Cancer Diagnosis and Treatment Open access
Jonathan Miksch, Dirk Bottke, Thomas Krohn, Reinhard Thamm, Detlef Bartkowiak, Christoph Solbach, +5 more
46citations -
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study2022 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz E. Joven-Ibáñez, +7 more
24citations -
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
Celia A J Michielsens, Nadine Boers, Nathan den Broeder, Mark H. Wenink, Aatke van der Maas, Elien A. M. Mahler, +5 more
21citations -
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study2023 Arthritis Research & Therapy article Medicine Spondyloarthritis Studies and Treatments Open access
Laure Gossec, Elke Theander, Soumya D. Chakravarty, Paul Bergmans, F. Lavie, Wim Noël, +3 more
3citations -
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results2021 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Josef S Smolen, Stefan Siebert, Tatiana V Korotaeva, Carlo Francesco Selmi, Paul Bergmans, Elisa Gremese, +9 more
34citations -
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2B and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Martín Rudwaleit, Irene E. van der Horst-Bruinsma, Floris A. van Gaalen, Nigil Haroon, Lianne S. Gensler, Myriam Manente, +4 more
0citations -
Disease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study2025 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Selinde V J Snoeck Henkemans, Marijn Vis, Gonul Hazal Koc, Jolanda Jacoba Luime, Marc R. Kok, Ilja Tchetverikov, +7 more
3citations -
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen–targeted Salvage Surgery
Sophie Knipper, Flemming Lischewski, Daniel Koehler, Matthias J. Eiber, Fijs W. B. van Leeuwen, Hilda A. de Barros, +14 more
21citations -
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis2021 Arthritis & Rheumatology article Medicine Spondyloarthritis Studies and Treatments Open access cited by 1 patent
Iain B. McInnes, Proton Rahman, Alice Bendix Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie Lillian Xu, +6 more
104citations -
Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study2020 Journal of Clinical Medicine article Medicine Prostate Cancer Diagnosis and Treatment Open access
Zeinab Paymani, Taryn J. Rohringer, Reza Vali, Wolfgang C. Loidl, Nafiseh Alemohammad, Hans Geinitz, +2 more
13citations -
Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic‐Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double‐Blind, Placebo‐Controlled APEX Study
Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, +7 more
0citations